Shares of Kane Biotech Inc. (CVE:KNE – Get Free Report) fell 23.1% during mid-day trading on Saturday . The stock traded as low as C$0.05 and last traded at C$0.05. 159,625 shares changed hands during mid-day trading, an increase of 120% from the average session volume of 72,560 shares. The stock had previously closed at C$0.07.
Kane Biotech Stock Down 23.1%
The company has a quick ratio of 0.39, a current ratio of 0.80 and a debt-to-equity ratio of -331.42. The stock’s 50-day simple moving average is C$0.08 and its 200 day simple moving average is C$0.10. The firm has a market cap of C$7.20 million, a P/E ratio of 1.25 and a beta of 0.52.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.
Featured Stories
- Five stocks we like better than Kane Biotech
- Trading Halts Explained
- A Large Oil Supply Draw Could Mean Upside in These 3 Energy Names
- What Are Growth Stocks and Investing in Them
- 3 Stocks Getting Rare Double Upgrades From Analysts
- How to trade using analyst ratings
- This Banking Giant Just Got a $90 Price Target Upgrade
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
